Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
2.290
+0.230 (11.17%)
At close: Jul 24, 2025, 4:00 PM
2.180
-0.110 (-4.80%)
After-hours: Jul 24, 2025, 7:59 PM EDT
Company Description
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases.
It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson’s disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer’s disease.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Telomir Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Erez Aminov |
Contact Details
Address: 100 SE 2nd Street, Suite 2000 #1009 Miami, Florida 33131 United States | |
| Phone | 786 396 6723 |
| Website | telomirpharma.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001971532 |
| CUSIP Number | 87975F104 |
| ISIN Number | US87975F1049 |
| Employer ID | 87-2606031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Alan Weichselbaum CPA, M.B.A. | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 23, 2025 | 8-K | Current Report |
| Jul 22, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 21, 2025 | 8-K | Current Report |
| May 21, 2025 | 8-K | Current Report |